OpGen (Nasdaq:OPGN) Shares Down 18% After 1-for-20 Reverse Stock Split

Shares of OpGen (NASDAQ: OPGN) Inc. declined 18% to $2.85 Thursday after the precision medicine company’s shares began trading on a reverse-split basis.

OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special Meeting held on November 30, 2022, will increase the market price per share of common stock in order to regain compliance with The Nasdaq Capital Market’s minimum bid price listing requirement of $1.00 per share.

In December, OPGN shares soared over 140% when the Company announced top-line data from its successfully completed Unyvero UTI clinical trial.

About OpGen, Inc. 

OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.

About the Author

OpGen (Nasdaq:OPGN) Shares Down 18% After 1-for-20 Reverse Stock Split

Joey Ramson